Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer

ACS Medicinal Chemistry Letters

Volumn 1, Issue 5, 2010, Pages 209-213

  Xu, Lianhong ^a   Liu, Hongtao ^a   Murray, Bernard P ^a   Callebaut, Christian ^a   Lee, Melody S ^a   Hong, Allen ^a   Strickley, Robert G ^a,b   Tsai, Luong K ^a   Stray, Kirsten M ^a   Wang, Yujin ^a   Rhodes, Gerry R ^a   Desai, Manoj C ^a  

^a Department of Medicinal Chemistry ^*  (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBICISTAT; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; GS 9350; RITONAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS RESISTANCE;

EID: 77956150896     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml1000257     Document Type: Article

References (31)

1. Hammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsh, M. S., Jacobsen, D. M., Montaner, J. S. G., Richman, D. D., Yeni, P. G., and Volberding, P. A. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society USA panel. J. Am. Med. Assoc. 2008, 300, 555 ? 570 and references therein.
2. Panel on Antiretroviral Guidelines for Adults and Adolescent, Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents; December 1, 2009; pp 1 ? 168 and references therein. Available at ContentFiles/AdultandAdolescentGL.pdf.
3. Willig, J. H., Abroms, S., Westfall, A. O., Routman, J., Adusumilli, S., Varshney, M., Allison, J., Chatham, A., Raper, J. L., Kaslow, R. A., Saag, M. S., and Mugavero, M. J. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008, 22, 1951 ? 1960 and references therein.
4. Parienti, J.-J., Bangsberg, D. R., Verdon, R., and Gardner, E. M. Better adherence with once-daily antiretroviral regimens: A meta-analysis. Clin. Infect. Dis. 2009, 48, 484 ? 488 and references therein.
5. Gerber, J. G. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin. Infect. Dis. 2000, 30 (Suppl. 2), S123 ? S129 and references therein.
6. Cooper, C. L.; van Heeswijk, R. P. G.; Gallicano, K.; Cameron, D. W. A review of low-dose ritonavir in protease inhibitor combination therapy Clin. Infect. Dis. 2003, 36, 1585-1592
7. Youle, M. Overview of boosted protease inhibitors in treatment- experienced HIV-infected patients. J. Antimicrob. Chemother. 2007, 60, 1195 ? 1205 and references therein.
8. Busse, K. H.; Penzak, S. R. Pharmacological enhancement of protease inhibitor with ritonavir: An update. Expert Rev. Clin. Pharmacol. 2008, 1, 533 ? 545 and references therein.
9. Kempf, D. J.; Marsh, K. C.; Kumar, G.; Rodrigues, A. D.; Denissen, J. F.; McDonald, E.; Kukulka, M. J.; Hsu, A.; Granneman, G. R.; Baroldi, P. A.; Sun, E.; Pizzuti, D.; Plattner, J. J.; Norbeck, D. W.; Leonard, J. M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir Antimicrob. Agents Chemother. 1997, 41, 654-660
10. von Moltke, L. L.; Durol, A. L. B.; Duan, S. X.; Greenblatt, D. J. Potent mechanism based inhibition of human CYP3A in vitro by amprenavir and ritonavir Eur. J. Clin. Pharmacol. 2000, 56, 259-261
11. Ernest, C. S., 2nd; Hall, S. D.; Jones, D. R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors J. Pharmacol. Exp. Ther. 2005, 312, 583-591
12. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions Drug Metab. Dispos. 2007, 35, 246-255
13. Mathias, A. A.; West, S.; Hui, J.; Kearney, B. P. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure Clin. Pharmacol. Ther. 2009, 85, 64-70
14. Xu, L.; Desai, M. C. Pharmacokinetic enhancers for HIV drugs Curr. Opin. Invest. Drugs 2009, 10, 775-786
15. Murray, B. P. Mechanism-based inhibition of CYP3A4 and other cytochromes P450 Annu. Rep. Med. Chem. 2009, 44, 535-551
16. DeJesus, E.; Berger, D.; Markowitx, M.; Cohen, C.; Hawkins, T.; Ruane, P.; Elion, R.; Farathing, C.; Zhong, L.; Cheng, A. K.; McColl, D.; Kearney, B. P. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients JAIDS 2006, 43, 1-5
17. Ramanathan, S.; Abel, S.; Tweedy, S.; West, S.; Hui, J.; Kearney, B. P. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc JAIDS 2010, 53, 209-214
18. Pozniak, A. L.; Boffito, M.; Russell, D.; Ridgway, C.; Muirhead, G. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects Br. J. Clin. Pharmacol. 2008, 65 (Suppl. 1) 54-59 and references therein.
19. Vierling, J.; Poordad, F.; Lawitz, E. Once daily narlaprevir (SCH 900518) in combination with PEGINTRON (peginterferon alfa-2b)/ribavirin for treatment-naïve subjects with genotype-1 CHC: Interim results from NEXT-1, a Phase 2a study. AASLD 2009, Abstract #LB4.
20. For illustration that ritonavir binds to HIV protease, see Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X.-P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484 ? 2488.
21. Barton, D. H. R.; McCombie, S. W. A new method for the deoxygenation of secondary alcohols J. Chem. Soc. Perkins I 1975, 1574
22. Xu, L.; Desai, M. C.; Liu, H. A novel and efficient synthesis of chiral C 2-symmetric 1,4-diamines Tetrahedron Lett. 2009, 50, 552-554
23. Bjornsson, T. D.; Callaghan, J. T.; Einolf, H. J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S. P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, R. S.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J. T.; Tweedie, D.; Vega, J. M.; Walsh, J.; Wrighton, S. A. The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31, 815 ? 832 and references therein.
24. Yang, J.; Liao, M.; Shou, M.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A. Cytochrome P450 turnover: Regulation of synthesis and degradation, methods for determining rates, and implications for the predictions of drug interactions. Curr. Drug Metab. 2008, 9, 384 ? 93 and references therein.
25. Mathias, A.; German, P.; Murray, B. P.; Wei, L.; Jain, A.; West, S.; Warren, D; Hui, J.; Kearney, B. P. Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity Clin. Pharmacol. Ther. 2010, 87, 322-329
26. FDA, HHS. Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling, 2006; http://www.fda.gov/cder/guidance/6695dft.pdf.
27. Kharasch, E. D.; Mitchell, D.; Coles, R.; Blanco, R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir Antimicrob. Agents Chemother. 2008, 52, 1663-1669
28. Foisy, M. M.; Yakiwchuk, E. M.; Hughes, C. A. Induction effects of ritonavir: Implications for drug interactions Ann. Pharmacother. 2008, 42, 1048-1059
29. Carr, A.; Samaras, K.; Burton, S.; Law, M.; Freund, J.; Chisholm, D. J.; Cooper, D. A. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 1998, 12, F51-F58
30. Gazzard, B.; Moyle, G. Dose atazanavir cause lipodystrophy? J. HIV Ther. 2004, 9, 41-44
31. Ramanathan, S.; Warren, D.; Wei, L.; Kearney, B. P. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. ICAAC 2009, Abstract #A1-1301.